PATENT CLAIM ANALYSIS

Application Number: 16359958
Application Type: Utility
Filing Date: 2019-03
Publication Date: 2019-07
Patent Classification: ["514", "289000"]

Abstract:
Dosage forms, drug delivery systems, and methods related to sustained release of dextromethorphan or improved therapeutic effects are disclosed. Typically, bupropion or a related compound is orally administered to a human being to be treated with, or being treated with, dextromethorphan.

Claim (Index 1):
A method of improving the efficacy of bupropion in treating depression, comprising: orally administering about 90 mg to about 125 mg of a bupropion in combination with about 0.3 mg/kg to about 1 mg/kg of a dextromethorphan, once or twice a day for at least 23 days, to a human being suffering from depression, wherein orally administering the bupropion in combination with the dextromethorphan is more effective in treating depression than orally administering the same dosage regimen of bupropion without dextromethorphan.

Metadata:
- Claim Count in Document: 80.0
- Percentile: 99.0
- Lexical Diversity: 1.45455
- Patent Class: 514.0
- Transitional Phrase Type: open
- Component Type: 1
- Foreign Priority: False
- Related Applications: ['15599163', '15621882', '15933075', '15688660', '15182253']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.8965103626891461
- 35 USC 102 Novelty (BERT): 0.682002313602438
- Combined Prediction Score: 0.8750595577804753
- Mean Citation Score: 725.0180499999999
- Max Citation Score: 727.90344
- Similarity Product: 516.3871075348807

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 0
- Claim Label 112: 0
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test